Log in with your email address username.


[Correspondence] STAMPEDE trial and patients with non-metastatic prostate cancer – Authors’ reply

We thank Giorgio Gandaglia and colleagues for the comments about our Article.1 Radiotherapy was encouraged from the start of the trial, particularly for N0M0 patients, who were at the lower-risk end of the spectrum in our STAMPEDE trial.1 However, radiotherapy was only mandated for this subgroup after the results of the MRC PR07/NCIC PR.3 and SPCG7 trials showed a survival advantage with radiotherapy.2,3 The planned use of radiotherapy was a stratifying factor at randomisation. Use of radiotherapy thus reflects relevant contemporary practice during recruitment.